Pinnacle Hill, LLC

In October 2018, Deerfield and the University of North Carolina at Chapel Hill announced the launch of Pinnacle Hill, LLC, a Deerfield company seeking to discover new medicines to address the significant unmet medical needs of our times.

Poseidon Innovation, LLC

In September 2018, Deerfield and University of California San Diego announced the launch of Poseidon Innovation, LLC, a Deerfield owned company that will support UC San Diego’s innovative research to accelerate early stage disease-curing therapeutics through a cross-disciplinary approach to drug development.

Lakeside Discovery, LLC

In May 2018, Northwestern University and Deerfield Management launched Lakeside Discovery with the mission to accelerate the translation of transformative biomedical technologies. Deerfield will provide up to $65 million of targeted funding and deep development and operational expertise to advance promising Northwestern research. Lakeside will tackle projects approved by a joint steering committee comprised of members from the Northwestern and Deerfield scientific leadership teams.

Ancora Innovation, LLC

In April 2018, Deerfield and Vanderbilt University announced the launch of Ancora Innovation, LLC, a Deerfield company that will support Vanderbilt’s innovative life science research and leverage Deerfield’s expertise in accelerating state-of-the-art drug development.

Bluefield Innovations, LLC

In October 2017, Deerfield and Johns Hopkins University entered into a collaboration by creating Bluefield Innovations, which is designed to catalyze the development of early stage therapeutics.

Press releases

Deerfield and The Johns Hopkins University Announce Collaboration to Catalyze Early Stage Therapeutic Research
November 2017

Bluefield Innovations Pursues Broadly Applicable Cancer Target
January 2018

Broad Institute

In October 2017, Deerfield launched a partnership with The Broad Institute of MIT and Harvard. The Broad Institute is a highly integrated biomedical and genomic research center that includes more than three thousand scientists committed to advancing research in areas such as infectious disease, cancer, psychiatric research and cardiovascular disease.

Bridge Medicines

Deerfield founded Bridge Medicines in October 2016 and committed to fund its operations. Bridge is a partnership between Deerfield, Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceuticals and another venture firm to establish a new drug discovery company. Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

Press releases

Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept
October 2016

Bridge Medicines Accepts Novel Small Molecule Targeting Basal Cell Carcinoma As First Drug Candidate for Development
March 2018

Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer
April 2018

Bridge Medicines Enters Agreement with Memorial Sloan Kettering to Develop Kidney‐Specific Delivery Platform for the Treatment of Acute Kidney Injury
July 2018